Cargando…
Allergy and Immunotherapy During the Pandemic
PURPOSE OF REVIEW: To summarize and review recent literature on the role of allergen immunotherapy in the setting of a worldwide pandemic. RECENT FINDINGS: At the start of the SARS-CoV-2 pandemic, most elective ambulatory patient care services, including allergen immunotherapy, were suspended. Now w...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8905013/ https://www.ncbi.nlm.nih.gov/pubmed/35281222 http://dx.doi.org/10.1007/s40136-022-00393-7 |
_version_ | 1784665088623378432 |
---|---|
author | Davis, Elizabeth Mahoney |
author_facet | Davis, Elizabeth Mahoney |
author_sort | Davis, Elizabeth Mahoney |
collection | PubMed |
description | PURPOSE OF REVIEW: To summarize and review recent literature on the role of allergen immunotherapy in the setting of a worldwide pandemic. RECENT FINDINGS: At the start of the SARS-CoV-2 pandemic, most elective ambulatory patient care services, including allergen immunotherapy, were suspended. Now with medical practices reopening, allergists must establish plans and protocols for resuming care of allergy patients, including strategies for restarting allergen immunotherapy. While there are no published evidence-based protocols for resuming allergen immunotherapy, limited scientific data and expert opinion suggest that the major factor in dose adjustment is the time elapsed from the last dose. SUMMARY: Resuming outpatient allergy services in the setting of the COVID-19 pandemic poses many challenges to the practitioner. Allergy specialists are now faced with developing prudent and evidence-based strategies for safely resuming allergen immunotherapy, while also maintaining a safe environment for staff and patients. |
format | Online Article Text |
id | pubmed-8905013 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-89050132022-03-09 Allergy and Immunotherapy During the Pandemic Davis, Elizabeth Mahoney Curr Otorhinolaryngol Rep Otolaryngic Allergy (M Platt and C Brook, Section Editors) PURPOSE OF REVIEW: To summarize and review recent literature on the role of allergen immunotherapy in the setting of a worldwide pandemic. RECENT FINDINGS: At the start of the SARS-CoV-2 pandemic, most elective ambulatory patient care services, including allergen immunotherapy, were suspended. Now with medical practices reopening, allergists must establish plans and protocols for resuming care of allergy patients, including strategies for restarting allergen immunotherapy. While there are no published evidence-based protocols for resuming allergen immunotherapy, limited scientific data and expert opinion suggest that the major factor in dose adjustment is the time elapsed from the last dose. SUMMARY: Resuming outpatient allergy services in the setting of the COVID-19 pandemic poses many challenges to the practitioner. Allergy specialists are now faced with developing prudent and evidence-based strategies for safely resuming allergen immunotherapy, while also maintaining a safe environment for staff and patients. Springer US 2022-03-09 2022 /pmc/articles/PMC8905013/ /pubmed/35281222 http://dx.doi.org/10.1007/s40136-022-00393-7 Text en © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Otolaryngic Allergy (M Platt and C Brook, Section Editors) Davis, Elizabeth Mahoney Allergy and Immunotherapy During the Pandemic |
title | Allergy and Immunotherapy During the Pandemic |
title_full | Allergy and Immunotherapy During the Pandemic |
title_fullStr | Allergy and Immunotherapy During the Pandemic |
title_full_unstemmed | Allergy and Immunotherapy During the Pandemic |
title_short | Allergy and Immunotherapy During the Pandemic |
title_sort | allergy and immunotherapy during the pandemic |
topic | Otolaryngic Allergy (M Platt and C Brook, Section Editors) |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8905013/ https://www.ncbi.nlm.nih.gov/pubmed/35281222 http://dx.doi.org/10.1007/s40136-022-00393-7 |
work_keys_str_mv | AT daviselizabethmahoney allergyandimmunotherapyduringthepandemic |